Even though medical diagnosis can be traced back to ancient Egypt in the 26th century BC (Edwin Smith Papyrus by Imhotep), in vitro diagnostics (IVD) as a field really started to take shape from late 20th century. Significant investments and research have been funnelled into early diagnosis of cancer with new products including next-generation sequencing, liquid biopsy and companion diagnostics, whilst payers are increasingly demanding biomarker stratification to justify the use of expensive drugs. Time and time again, the healthcare industry is buzzing with new ideas on how to use next generation diagnostics to achieve “smart healthcare,” but to date, this has not been realised. Yet, the unmet needs remain with ballooning healthcare cost, aging society and changes in disease trends.
Are Diagnostics Poised to Lead Healthcare Or Is This Another False Positive?Download Request
At PharmaVentures, a data room is used as a location to store essential documents that are needed during an M&A or Divestment transaction. It is an essential part of the due diligence process which interested buyers access prior to closing a transaction. We routinely use Virtual Data Rooms (VDR) from third-party providers of which there are many. All provide similar functionality but three essential features are the ability to permission document access to an individual user level, feedback on user activity, and a copy of all activity that took place in the VDR as an audit trail.
Data Room Structure GuidelineDownload Request
Haematological malignancies are types of cancers affecting blood, bone marrow and lymph nodes. Broadly speaking, there are three major types of blood cancers: leukaemia, lymphoma and myeloma. Of these, the most common blood cancer types include non-Hodgkin lymphoma (NHL), chronic lymphocytic leukaemia (CLL), acute myeloid leukaemia (AML) and multiple myeloma (MM). In the US, a newly diagnosed blood cancer patient is reported every three minutes, and new cases of blood cancers account for approximately 10% of all new cancer diagnoses. Also, an estimated 1.3 million people in the US are either living with or are in remission from blood cancer. Scientific and technological advances have led to a significant improvement in five-year relative survival rates for blood cancers, having more than doubled for lymphoma and more than quadrupled for myeloma and leukaemia over the last 50 years.
The evolving therapeutic landscape in haematologic malignanciesDownload Request
As you are aware PharmaVentures is a sector focused advisory firm and we are at the forefront of deal-making activity in the pharmaceutical, biotech, medtech and service sector industries such as CROs and CDMOs. Given the current backdrop and challenges facing companies executing live transactions or contemplating entering acquisition or divestment processes, we thought it may be useful to share with you our thoughts on the current deal-making environment and what we see in the ‘trenches’ of ongoing processes for our clients.